Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer
- Allarity Therapeutics focuses on advancing stenoparib in advanced recurrent ovarian cancer based on positive Phase 2 trial data.
- The company aims to address an unmet medical need and reduce costs by deprioritizing other clinical trials.
- Stenoparib shows promising clinical benefit and duration, exceeding expectations in advanced ovarian cancer patients.
- The strategic pivot aligns with the growing PARP inhibitor market, expected to reach $22 billion in revenue by 2028.
- Stenoparib's unique mechanism of action and favorable safety profile position it as a next-generation alternative in the ovarian cancer treatment market.
- None.
Insights
The strategic prioritization of stenoparib by Allarity Therapeutics signals a noteworthy shift in the oncology landscape, particularly for advanced recurrent ovarian cancer. From a clinical perspective, the dual inhibition of PARP and tankyrase by stenoparib could offer a therapeutic advantage, potentially addressing the resistance seen with current PARP inhibitors. Moreover, the DRP® platform's ability to pre-select patients likely to benefit from stenoparib could lead to more personalized and effective treatments.
However, the challenge remains in demonstrating consistent efficacy across a broader patient cohort, as well as in comparing the long-term outcomes of stenoparib with existing treatments. The favorable toxicity profile mentioned is encouraging, as it may improve patient quality of life and compliance with the treatment regimen. Nevertheless, further data is necessary to fully understand the implications of tankyrase inhibition on cancer progression and patient survival.
From a financial standpoint, Allarity Therapeutics' decision to concentrate resources on stenoparib development is a strategic move that could potentially capitalize on the unmet needs within the PARP inhibitor market. The referenced market projections and recent acquisition activities underscore the high commercial stakes involved. The company's ability to reduce costs while reallocating resources towards stenoparib could improve its financial position and investor appeal, particularly if the drug advances towards registration and captures market share.
Investors should monitor the progression of stenoparib's clinical trials and regulatory milestones, as these will be critical in determining the company's financial trajectory. Furthermore, considering the historical significance of partnerships in this sector, Allarity Therapeutics could become an attractive collaboration or acquisition target if stenoparib demonstrates compelling clinical results.
Examining the market dynamics, the withdrawal of certain PARP inhibitors for heavily pretreated ovarian cancer patients creates a gap that stenoparib could potentially fill. The drug's unique dual mechanism of action not only positions it favorably for ovarian cancer but also suggests potential applicability in other solid tumors with upregulated WNT pathways.
Market acceptance, however, will depend on the drug's comparative effectiveness and safety profile, as well as the company's ability to navigate the competitive landscape. The DRP® technology offers a differentiating factor that may lead to improved patient outcomes and cost-effectiveness, which are increasingly important considerations for payers and healthcare providers.
- The stenoparib Phase 2 monotherapy trial in advanced, recurrent ovarian cancer continues to show promise, prompting shift in resources to accelerate stenoparib development
- Further development of IXEMPRA® and dovitinib is de-prioritized
- The Company has been able to reduce costs materially
Boston (March 27, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced a strategic pivot aimed at advancing its clinical-stage candidate stenoparib, a novel PARP/Tankyrase dual inhibitor, toward registration in advanced recurrent ovarian cancer, leveraging its DRP® platform to identify and enroll only the patients most likely to derive clinical benefit.
This decision is the outcome of an extensive analysis of the Company’s strategic opportunities, initiated immediately after Thomas Jensen stepped into his role as Interim CEO in early December 2023. In partnership with Executive Advisor Jeremy R. Graff, PhD and in agreement with the Board of Directors, this analysis was meticulously carried out with a dual objective: to rapidly channel the Company’s proprietary DRP® technology towards benefiting a patient population with an unmet medical need while at the same time taking the clinical risk/reward balance as well as commercial and regulatory probabilities of success into consideration.
This decisive shift in priorities is driven by the compelling initial data from the Phase 2 monotherapy trial evaluating stenoparib in advanced, recurrent ovarian cancer patients, as announced on December 5, 2023.
For this trial, the patients enrolled have advanced through multiple lines of therapy, including platinum, taxanes, anti-angiogenesis inhibitors, and even the recently approved Antibody Drug Conjugate, Elahere. Importantly, all but two enrolled patients to date have been previously treated with a PARP inhibitor. These patients have few, if any, effective treatment options and typically advance through available therapies after only a few months.
Emerging and maturing data continue to show that the clinical benefit and duration on stenoparib are substantially exceeding expectations:
- Clinical benefit has now exceeded 20 weeks for each of the five patients originally mentioned in the December release, with the first patient on trial remaining on treatment for more than ten months.
- The Complete Responder, referenced in the December release, has confirmed continued response through multiple additional scans and remains on therapy.
- Durable clinical benefit is evident in patients with:
- Platinum-sensitive or resistant disease.
- Homologous repair proficient or deficient tumors; and
- both BRCA-wt or mutant cancers.
- These points highlight the differentiated mechanism of therapeutic action for stenoparib and accentuate the benefit of pre-selecting patients with DRP®.
These data have prompted the Company to funnel its finances and internal resources to accelerate stenoparib development for this advanced patient population.
Interim CEO of Allarity Thomas Jensen stated, “There remains a clear unmet medical need in patients with advanced ovarian cancer whose treatment options are limited to standard, older chemotherapies that provide limited benefit and come with significant toxicity. Based on the favorable tolerability with stenoparib and the emerging clinical benefit evident in our patients so far, we have decided to focus on re-tooling our company to accelerate development of stenoparib toward registration as quickly as possible for these desperately ill patients.”
As part of this strategic shift, the Company will deprioritize the other clinical trials for dovitinib and IXEMPRA®.
An additional outcome of the strategic review is that Allarity Therapeutics has been able to materially reduce its ongoing costs and cash burn and still prioritize stenoparib to better align with its new strategic priorities.
Several factors outside the Company have been included in the above-mentioned analysis of the Company’s strategic opportunities. This includes that the PARP inhibitor market, expected to reach
About stenoparib
Stenoparib is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and Tankyrase 1 and 2. At present, tankyrases are attracting significant attention as emerging therapeutic targets for cancer, principally due to their role in regulating the Wnt signaling pathway. Aberrant Wnt/β-catenin signaling has been implicated in the development and progression of numerous cancers. By inhibiting PARP and blocking Wnt pathway activation, stenoparib’s unique therapeutic action shows potential as a promising therapeutic. Allarity has exclusive global rights for the development and commercialization of stenoparib, which was originally developed by Eisai Co. Ltd. and was formerly known under the names E7449 and 2X-121.
About the Drug Response Predictor – DRP® Companion Diagnostic
Allarity uses its drug-specific DRP® to select those patients who, by the expression signature of their cancer, are found to have a high likelihood of benefiting from a specific drug. By screening patients before treatment, and only treating those patients with a sufficiently high, drug-specific DRP score, the therapeutic benefit rate may be significantly increased. The DRP method builds on the comparison of sensitive vs. resistant human cancer cell lines, including transcriptomic information from cell lines combined with clinical tumor biology filters and prior clinical trial outcomes. DRP is based on messenger RNA expression profiles from patient biopsies. The DRP® platform has proven its ability to provide a statistically significant prediction of the clinical outcome from drug treatment in cancer patients in 37 out of 47 clinical studies that were examined (both retrospective and prospective). The DRP platform, which can be used in all cancer types and is patented for more than 70 anti-cancer drugs, has been extensively published in the peer-reviewed literature.
About Allarity Therapeutics
Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage biopharmaceutical company dedicated to developing personalized cancer treatments. The Company is focused on development of stenoparib, a novel PARP/Tankyrase inhibitor for advanced ovarian cancer patients, using its DRP® companion diagnostic for patient selection in the ongoing phase 2 clinical trial, NCT03878849. Allarity is headquartered in the U.S., with a research facility in Denmark, and is committed to addressing significant unmet medical needs in cancer treatment. For more information, visit www.allarity.com.
Follow Allarity on Social Media
LinkedIn: https://www.linkedin.com/company/allaritytx/
X: https://twitter.com/allaritytx
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide the Company’s current expectations or forecasts of future events. The words “anticipates,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predicts,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements related to any statements related to the de-prioritization of the other clinical trials for dovitinib and IXEMPRA®, and any statements concerning an acceleration of the stenoparib development. Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that the Company is not able to raise sufficient capital to support its current and anticipated clinical trials, the risk that early results of a clinical study do not necessarily predict final results and that one or more of the clinical outcomes may materially change following more comprehensive reviews of the data, and as more patient data become available, the risk that results of a clinical study are subject to interpretation and additional analyses may be needed and/or may contradict such results, the receipt of regulatory approval for stenoparib or any of our other therapeutic candidates and companion diagnostics or, if approved, the successful commercialization of such products, the risk of cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies will not be repeated or observed in ongoing or future studies involving our therapeutic candidates, and the risk that the current COVID-19 pandemic will impact the Company’s current and future clinical trials and the timing of the Company’s preclinical studies and other operations. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in our Form S-1 registration statement filed on October 30, 2023, as amended and our Form 10-K annual report on file with the Securities and Exchange Commission (the “SEC”), available at the SEC’s website at www.sec.gov, and as well as discussions of potential risks, uncertainties and other important factors in the Company’s subsequent filings with the SEC. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law.
###
Company Contact:
investorrelations@allarity.com
Media Contact:
Thomas Pedersen
Carrotize PR & Communications
+45 6062 9390
tsp@carrotize.com
Attachment
FAQ
What is Allarity Therapeutics focusing on in the strategic pivot?
Why is the company deprioritizing IXEMPRA® and dovitinib?
What clinical benefit has stenoparib shown in advanced ovarian cancer patients?
What market trend is Allarity Therapeutics aligning with through this strategic pivot?
What makes stenoparib unique in the ovarian cancer treatment market?
